RxDoctor Payments DataLook up a doctor →

Charles Markle, MD

Neurology · Mobile, ALNPI 1194774927

Payments from drug & device makers

$211,510in general payments, 2019–2025

Across 2,194 payments — averaging $96.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$65K
  • Lilly USA, LLC$47K
  • EMD Serono, Inc.$47K
  • Teva Pharmaceuticals USA, Inc.$21K
  • Sanofi$9K
  • Novartis$3K
  • plus $20K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)529$64,719
Lilly USA, LLC167$47,400
EMD Serono, Inc.87$46,888
Teva Pharmaceuticals USA, Inc.91$20,531
Sanofi36$9,442
Novartis191$2,722
Supernus Pharmaceuticals, Inc.107$2,711
Lundbeck LLC102$1,404
Bristol Myers Squibb42$1,317
UCB, Inc.65$1,263
Biogen87$1,134
SK Life Science, Inc.44$1,091
Acadia Pharmaceuticals Inc51$991
Eisai Inc.45$839
Pfizer55$760
Amgen(2 entities)42$710
AstraZeneca(2 entities)32$679
MDD US Operations, LLC35$521
Argenx US, Inc.13$393
Mallinckrodt Hospital Products Inc.18$371
Impel Pharmaceuticals Inc.32$369
Biohaven Pharmaceutical Holding Company Ltd.33$345
Johnson & Johnson(2 entities)14$332
Acorda Therapeutics, Inc16$288
Adamas Pharmaceuticals, Inc.14$287
Genentech USA, Inc.18$280
Neurocrine Biosciences, Inc.17$277
Tanabe Pharma America, Inc.14$266
Sunovion Pharmaceuticals Inc.20$248
Kyowa Kirin, Inc.12$214
Grifols USA, LLC10$210
Neurelis, Inc.11$206
ANI Pharmaceuticals, Inc.9$192
CSL Behring6$185
Alnylam Pharmaceuticals Inc.7$176
Ipsen Biopharmaceuticals, Inc10$171
Biohaven Pharmaceuticals, Inc.24$152
Arbor Pharmaceuticals, Inc.9$131
Amneal Pharmaceuticals LLC8$118
TG Therapeutics, Inc.5$85
Scilex Pharmaceuticals Inc.4$80
Greenwich Biosciences, Inc.4$72
Mallinckrodt Enterprises LLC5$70
Abbott4$67
Zyla Life Sciences, Inc.4$63
Medtronic4$62
Azurity Pharmaceuticals, Inc.4$54
Upsher-smith Laboratories LLC4$54
Catalyst Pharmaceuticals, Inc.3$52
Boston Scientific2$50
Averitas Pharma Inc.3$45
Avanir Pharmaceuticals, Inc.3$44
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$43
Takeda Pharmaceuticals U.S.A., Inc.2$43
Merz North America, Inc.2$42
Axsome Therapeutics, Inc.2$41
Merz Pharmaceuticals, LLC2$33
Jazz Pharmaceuticals Inc.2$33
Life Molecular Imaging Ltd1$25
Otsuka America Pharmaceutical, Inc.1$22

How this compares

$211,510 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$420,860
Medicare patients
842
Services billed
27,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →